HER2/neu is a protein involved in normal cell growth. It is found on some types of cancer cells, including breast and ovarian. Cancer cells removed from the body may be tested for the presence of HER2/neu to help decide the best type of treatment. HER2/neu is a type of receptor tyrosine kinase. Also called c-erbB-2, human EGF receptor 2, and human epidermal growth factor receptor 2.
A novel therapy designed to help stimulate the body's immune system response against cancer appears to be safe to use as alone or in combination with immune checkpoint inhibitors.
Biophysicists have developed a method for modifying the surface of micro- and nanoparticles — tiny structures measuring between a thousandth and a millionth of a millimeter — by covering them with biological molecules. Engineered in this way, the particles can serve as both therapeutic and diagnostic agents, delivering drugs to cancer cells.
Oxis Biotech, Inc., a wholly owned subsidiary of Oxis International, Inc., announced today the execution of a definitive licensing and development agreement with MultiCell Immunotherapeutics, Inc. concerning the development of certain antibody-drug conjugates (ADCs).
Caris Life Sciences®, a leading biosciences company focused on fulfilling the promise of precision medicine, announced today the presentation of clinical data from studies demonstrating the potential utility of comprehensive molecular profiling in guiding treatment of patients with gynecologic malignancies, including breast cancers and ovarian cancer.
Results from the PrefHer (Patient Preference for Subcutaneous (SC) versus Intravenous (IV) Herceptin) trial show that 92% of early HER2-positive breast cancer patients favoured quicker SC administration of Herceptin compared to the standard IV infusion.1 Presented at the St. Gallen Breast Cancer Conference in Switzerland.
Quinten, a strategic and operational consulting company specializing in the evaluation of biomedical data in the pharmaceutical, biotechnology and cosmetic industries, today announces the identification of two discriminating biological marker candidates which are indicative of a favorable response to treatment in women suffering from triple-negative breast cancer (TNBC).
Scientists at Weill Cornell Medical College have discovered the molecular switch that allows aggressive triple negative breast cancer cells to grow the amoeba-like protrusions they need to crawl away from a primary tumor and metastasize throughout the body. Their findings, published in Cancer Cell, suggest a novel approach for developing agents to treat cancer once it has spread.
Most triple-negative breast cancer patients who were treated with chemotherapy to shrink the tumor prior to surgery still had multiple genetic mutations in their tumor cells, according to a study by Vanderbilt-Ingram Cancer Center (VICC) investigators.
Research from The Cancer Institute of New Jersey (CINJ) shows that women with triple-negative breast cancer and no more than three positive lymph nodes following a mastectomy have a higher risk of local recurrence than similar women whose disease is not classified as triple-negative.
Breast cancer recurrence is a major problem after treatment of localized breast cancer. The risk of recurrence depends on several factors including the stage of presentation and the biology of the disease.
Researchers at the Perelman School of Medicine at the University of Pennsylvania report that a short course of vaccination with an anti-HER2 dendritic cell vaccine made partly from the patient's own cells triggers a complete tumor eradication in nearly 20 percent of women with ductal carcinoma in situ (DCIS), an early breast cancer.
ARUP Laboratories, a leading national clinical and anatomic pathology reference laboratory and a leader in innovative laboratory research and development, today announced the availability of a new laboratory developed test designed to classify breast cancer into clinically significant molecular subtypes that are important for the management of the disease.
Women with ductal carcinoma in situ (DCIS) who exhibit an overexpression of the protein HER2/neu have a six-fold increase in risk of invasive breast cancer, according to a new study from the University of Pennsylvania School of Medicine.
Light directed at a breast tumor through a needle can provide pathologists with biological specifics of the tumor and help oncologists choose treatment options that would be most effective for that individual patient.
Using laboratory and mouse models of human breast cancer, researchers have found that a small molecule capable of targeting specific proteins on the surface of breast cancer cells can inhibit the growth of breast cancer cells that migrate to the brain.
Genetic variations ensure that no two people are exactly alike, nor are their cancers.
Italian scientists announced (Monday September 24) that they have found a new and promising target for anti-tumour therapy in cancer.
Risk of congestive heart failure in women treated with trastuzumab (Herceptin) and combination chemotherapy for early-stage breast cancer did not increase over time according to a five-year follow-up of National Surgical Adjuvant Breast and Bowel Project (NSABP) trial B-31, presented at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago.
Researchers at the Kimmel Cancer Center at Jefferson in Philadelphia have devised a novel method to expand the number of immune system "natural killer (NK)" cells from blood cells outside the body.
With the help of immune system-stimulating molecules that mimic bacterial components, researchers have used a type of cancer vaccine to both delay and prevent breast tumors in mice.